{
  "CitationSubset": [],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33442665",
  "DateCompleted": {
    "Year": "2022",
    "Month": "02",
    "Day": "25"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "02",
    "Day": "25"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "01",
        "Day": "04"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "pkaa111",
      "10.1093/jncics/pkaa111"
    ],
    "Journal": {
      "ISSN": "2515-5091",
      "JournalIssue": {
        "Volume": "5",
        "Issue": "1",
        "PubDate": {
          "Year": "2021",
          "Month": "Feb"
        }
      },
      "Title": "JNCI cancer spectrum",
      "ISOAbbreviation": "JNCI Cancer Spectr"
    },
    "ArticleTitle": "Associations Between Amplification (1q) and Prior Cancer in a Real-World De Novo Myeloma Cohort.",
    "Abstract": {
      "AbstractText": [
        "Genomic biomarkers inform treatment in multiple myeloma (MM), making patient clinical data a potential window into MM biology. We evaluated de novo MM patients for associations between specific MM cytogenetic patterns and prior cancer history. Analyzing a MM real-world dataset, we identified a cohort of 1769 patients with fluorescent in situ hybridization cytogenetic testing at diagnosis. Of the patients, 241 (0.14) had histories of prior cancer(s). Amplification of the long arm of chromosome 1 [amp(1q)] varied by prior cancer history (0.31 with prior cancer vs 0.24 without; 2-sided <i>P</i>\u2009=\u2009.02). No other MM translocations, amplifications, or deletions were associated with prior cancers. Amp(1q) and cancer history remained strongly associated in a logistic regression adjusting for patient demographic and disease attributes. The results merit follow-up regarding carcinogenic treatment effects and screening strategies for second malignancies. Broadly, the findings suggest that analyses of patient-level phenotypic-genomic real-world dataset may accelerate cancer research through hypothesis-generating studies."
      ],
      "CopyrightInformation": "\u00a9 The Author(s) 2021. Published by Oxford University Press."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "COTA, Boston, MA, USA."
          }
        ],
        "LastName": "Lamont",
        "ForeName": "Elizabeth B",
        "Initials": "EB"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Massachusetts General Hospital Cancer Center, Boston, MA, USA."
          }
        ],
        "LastName": "Yee",
        "ForeName": "Andrew J",
        "Initials": "AJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "John Theurer Cancer Center, Hackensack, NJ, USA."
          }
        ],
        "LastName": "Goldberg",
        "ForeName": "Stuart L",
        "Initials": "SL"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "John Theurer Cancer Center, Hackensack, NJ, USA."
          }
        ],
        "LastName": "Siegel",
        "ForeName": "David S",
        "Initials": "DS"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "COTA, Boston, MA, USA."
          }
        ],
        "LastName": "Norden",
        "ForeName": "Andrew D",
        "Initials": "AD"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "JNCI Cancer Spectr",
    "NlmUniqueID": "101721827",
    "ISSNLinking": "2515-5091"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Biomarkers, Tumor"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Genetic Markers"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged, 80 and over"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Biomarkers, Tumor"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Chromosomes, Human, Pair 1"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cohort Studies"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Gene Amplification"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Gene Deletion"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Genetic Markers"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "In Situ Hybridization, Fluorescence"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Logistic Models"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Multiple Myeloma"
    },
    {
      "QualifierName": [
        "epidemiology",
        "genetics"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Translocation, Genetic"
    }
  ]
}